Zentalis Pharmaceuticals Inc 's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Zentalis Pharmaceuticals Inc 's ROA in the second quarter of 2026?
Zentalis Pharmaceuticals Inc recorded a cumulative net loss of $-140 million during 12 months ending in the second quarter of 2026, resulting in a negative return on assets (ROA) of -51.46%.

However, within the Healthcare sector 571 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 3799, from total ROA ranking in the first quarter of 2026 at 4461.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Total Assets Change	-38.78 %	-34.1 %	-26.8 %	-19.99 %	-21.61 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-140	-124	-137	-149	-163
Return On Assets (TTM)	-51.46 %	-40.67 %	-40.55 %	-40.97 %	-42.29 %
ZNTL's Total Ranking	# 3799	# 4461	# 3901	# 3954	# 4166
Total Assets (TTM) in million	215	253	289	327	352
Seq. Total Assets Change	-14.91 %	-12.42 %	-11.7 %	-6.95 %	-8.41 %
Seq. Net Income Change	-	-	-	-	-

ZNTL's 5 Years Annual ROA >> Back to ZNTL Management Effectiveness >> Compare ZNTL ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 249
Sector	# 572
Overall	# 3911

Return On Assets Statistics
High	Average	Low
-34.37 %	-44.17 %	-52.67 %
(Dec 31 2024)		(Jun 30 2021)

Financial Statements
Zentalis Pharmaceuticals Inc 's Assets	$ 215 million	ZNTL's Balance sheet
Zentalis Pharmaceuticals Inc 's Income	$ -42 million	Quarterly ZNTL's Income Statement
ZNTL's Income by Division		See ZNTL's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021
Y / Y Total Assets Change	-26.8 %	-22.94 %	4.42 %	11.69 %	22.44 %
Total Assets in million	289	395	512	491	439
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-137	-166	-292	-237	-166
Annual Return On Assets	-47.43 %	-42.02 %	-57.06 %	-48.33 %	-37.81 %

ZNTL's 5 Years Annual ROA >> Back to ZNTL Management Effectiveness >> Compare ZNTL ROA to its Competitors

More Return On Assets Ratios
ZNTL's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
ZNTL's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for ZNTL's Competitors
Subscribers only: Roa for Zentalis Pharmaceuticals Inc 's Suppliers
Subscribers only: Return On Assets for ZNTL's Customers

You may also want to know
ZNTL's Roi	ZNTL's Inventory Turnover Ratio	ZNTL's Growth Rates	ZNTL's Dividend Comparisons
	ZNTL's Profitability Ratios	ZNTL's Asset Turnover Ratio	ZNTL's Dividend Growth
ZNTL's Roe	ZNTL's Valuation Ratios	ZNTL's Financial Strength Ratios	ZNTL's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector

ROA

Date modified: 2026-09-05T15:41:29+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.